UA82895C2 - Застосування частин та/або екстрактів опунції для лікування депресій - Google Patents
Застосування частин та/або екстрактів опунції для лікування депресій Download PDFInfo
- Publication number
- UA82895C2 UA82895C2 UAA200603519A UAA200603519A UA82895C2 UA 82895 C2 UA82895 C2 UA 82895C2 UA A200603519 A UAA200603519 A UA A200603519A UA A200603519 A UAA200603519 A UA A200603519A UA 82895 C2 UA82895 C2 UA 82895C2
- Authority
- UA
- Ukraine
- Prior art keywords
- disorders
- prickly
- diseases
- extracts
- depression
- Prior art date
Links
- 240000001439 Opuntia Species 0.000 title claims abstract description 35
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 title claims description 32
- 208000020401 Depressive disease Diseases 0.000 title claims description 20
- 239000000284 extract Substances 0.000 claims abstract description 29
- 241000196324 Embryophyta Species 0.000 claims abstract description 19
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 7
- 208000020925 Bipolar disease Diseases 0.000 claims abstract description 7
- 206010036618 Premenstrual syndrome Diseases 0.000 claims abstract description 7
- 230000036506 anxiety Effects 0.000 claims abstract description 7
- 208000028683 bipolar I disease Diseases 0.000 claims abstract description 7
- 208000025307 bipolar depression Diseases 0.000 claims abstract description 7
- 208000019906 panic disease Diseases 0.000 claims abstract description 7
- 208000027520 Somatoform disease Diseases 0.000 claims abstract description 6
- 230000036651 mood Effects 0.000 claims abstract description 4
- 208000027534 Emotional disease Diseases 0.000 claims description 11
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 11
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 240000003537 Ficus benghalensis Species 0.000 claims description 8
- 206010002942 Apathy Diseases 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000002996 emotional effect Effects 0.000 claims description 5
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 5
- 229960004688 venlafaxine Drugs 0.000 claims description 5
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 claims 4
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 3
- 206010012374 Depressed mood Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 201000003995 melancholia Diseases 0.000 claims 2
- 206010033664 Panic attack Diseases 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 abstract description 6
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 230000003001 depressive effect Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229960004801 imipramine Drugs 0.000 description 3
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101000964584 Homo sapiens Zinc finger protein 160 Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000004727 Opuntia ficus indica Nutrition 0.000 description 1
- 240000009297 Opuntia ficus-indica Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102100040815 Zinc finger protein 160 Human genes 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- -1 and the like Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10350194A DE10350194B4 (de) | 2003-10-28 | 2003-10-28 | Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen |
| PCT/EP2004/012070 WO2005041994A1 (de) | 2003-10-28 | 2004-10-26 | Verwendung von feigenkaktus (opuntia) pflanzenteilen und/oder extrakten behandlung von depressionen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA82895C2 true UA82895C2 (uk) | 2008-05-26 |
Family
ID=34529823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200603519A UA82895C2 (uk) | 2003-10-28 | 2004-10-26 | Застосування частин та/або екстрактів опунції для лікування депресій |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070134355A1 (ja) |
| EP (1) | EP1682162B1 (ja) |
| JP (1) | JP4863875B2 (ja) |
| KR (1) | KR20070026329A (ja) |
| CN (1) | CN1867346B (ja) |
| AT (1) | ATE388719T1 (ja) |
| AU (1) | AU2004285274B2 (ja) |
| BR (1) | BRPI0415945A (ja) |
| CA (1) | CA2544050C (ja) |
| DE (2) | DE10350194B4 (ja) |
| ES (1) | ES2299878T3 (ja) |
| PL (1) | PL1682162T3 (ja) |
| PT (1) | PT1682162E (ja) |
| RU (1) | RU2336087C2 (ja) |
| UA (1) | UA82895C2 (ja) |
| WO (1) | WO2005041994A1 (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2885524B1 (fr) * | 2005-05-10 | 2007-08-10 | Silab Sa | Procede d'obtention d'un actif cosmetique exfoliant, principe actif obtenu et compositions associees |
| WO2008038849A1 (en) * | 2006-09-29 | 2008-04-03 | Korea Institute Of Science And Technology | Pharmaceutical composition comprising an extract from opuntia ficus-indica |
| IL182284A0 (en) * | 2007-03-29 | 2008-01-20 | Avi Gal | A composition and method for inhibiting the enzyme 5 - alpha - reductase and the alpha - 1 - adrenergic receptor, treating related disorders, and a process for producing said composition |
| US7722904B2 (en) * | 2007-11-01 | 2010-05-25 | Access Business Group International Llc | Compositions and methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid |
| EP2057994A1 (de) | 2007-11-06 | 2009-05-13 | Finzelberg GmbH & Co. KG | Feigenkakteen-Extraktzubereitung |
| AT507988B1 (de) * | 2009-01-15 | 2012-06-15 | Kaahee Res And Dev Gmbh | Kaktusfruchtextrakt |
| US20100209557A1 (en) * | 2009-02-14 | 2010-08-19 | O'connor Daniel C | Recovery blends for liquid beverages |
| MX2012009288A (es) * | 2010-02-11 | 2013-01-24 | Schwabe Willmar Gmbh & Co | Uso de triglicosidos de isorhamnetina. |
| MA34856B1 (fr) * | 2012-07-09 | 2014-02-01 | Mariam Minhaj | Procédure d'obtenir une préparation à base des fleurs de cactus, et son utilisation |
| WO2020256243A1 (ko) * | 2019-06-17 | 2020-12-24 | 한국한의학연구원 | 부채마와 백년초의 혼합추출물을 포함하는 우울증 예방 또는 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9621486D0 (en) * | 1996-10-15 | 1996-12-04 | Isis Innovation | Oxygenase enzymes & method |
| UA77145C2 (en) * | 1997-11-05 | 2006-11-15 | Wyeth Corp | Extended release dosage formulation |
| GB9810092D0 (en) * | 1998-05-11 | 1998-07-08 | Merck Sharp & Dohme | Therapeutic agents |
| US6197828B1 (en) * | 1998-12-01 | 2001-03-06 | Sepracor, Inc. | Derivatives of (+)-venlafaxine and methods of preparing and using the same |
| MY124001A (en) * | 1999-04-23 | 2006-06-30 | E Excel Int | Dietary supplements containing dehydrated cactus fruit juice and ginseng berry juice |
| FR2823423B1 (fr) * | 2001-04-11 | 2004-08-27 | Bio Serae Laboratoires | Preparation a base de cactaceae ayant la propriete de fixer les graisses, et procede d'obtention d'une telle preparation |
| KR100523562B1 (ko) * | 2001-10-29 | 2005-10-25 | 한국과학기술연구원 | 손바닥선인장 추출물 및 이로부터 분리된 화합물을함유하는 신경세포 보호용 조성물 |
-
2003
- 2003-10-28 DE DE10350194A patent/DE10350194B4/de not_active Expired - Fee Related
-
2004
- 2004-10-26 US US10/577,624 patent/US20070134355A1/en not_active Abandoned
- 2004-10-26 UA UAA200603519A patent/UA82895C2/uk unknown
- 2004-10-26 AT AT04790853T patent/ATE388719T1/de active
- 2004-10-26 PL PL04790853T patent/PL1682162T3/pl unknown
- 2004-10-26 AU AU2004285274A patent/AU2004285274B2/en not_active Ceased
- 2004-10-26 WO PCT/EP2004/012070 patent/WO2005041994A1/de active IP Right Grant
- 2004-10-26 CA CA2544050A patent/CA2544050C/en not_active Expired - Fee Related
- 2004-10-26 DE DE502004006525T patent/DE502004006525D1/de active Active
- 2004-10-26 PT PT04790853T patent/PT1682162E/pt unknown
- 2004-10-26 RU RU2006117208/15A patent/RU2336087C2/ru not_active IP Right Cessation
- 2004-10-26 BR BRPI0415945-4A patent/BRPI0415945A/pt not_active IP Right Cessation
- 2004-10-26 ES ES04790853T patent/ES2299878T3/es active Active
- 2004-10-26 EP EP04790853A patent/EP1682162B1/de not_active Not-in-force
- 2004-10-26 KR KR1020067008209A patent/KR20070026329A/ko not_active Application Discontinuation
- 2004-10-26 CN CN2004800304073A patent/CN1867346B/zh not_active Expired - Fee Related
- 2004-10-26 JP JP2006537161A patent/JP4863875B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP4863875B2 (ja) | 2012-01-25 |
| AU2004285274A1 (en) | 2005-05-12 |
| BRPI0415945A (pt) | 2007-01-02 |
| ES2299878T3 (es) | 2008-06-01 |
| KR20070026329A (ko) | 2007-03-08 |
| RU2006117208A (ru) | 2007-12-10 |
| DE10350194B4 (de) | 2005-11-10 |
| WO2005041994A1 (de) | 2005-05-12 |
| CN1867346B (zh) | 2012-08-22 |
| CN1867346A (zh) | 2006-11-22 |
| ATE388719T1 (de) | 2008-03-15 |
| PT1682162E (pt) | 2008-03-28 |
| RU2336087C2 (ru) | 2008-10-20 |
| EP1682162A1 (de) | 2006-07-26 |
| US20070134355A1 (en) | 2007-06-14 |
| DE502004006525D1 (de) | 2008-04-24 |
| CA2544050C (en) | 2014-07-08 |
| CA2544050A1 (en) | 2005-05-12 |
| AU2004285274B2 (en) | 2009-12-24 |
| JP2007509877A (ja) | 2007-04-19 |
| PL1682162T3 (pl) | 2008-08-29 |
| DE10350194A1 (de) | 2005-06-16 |
| EP1682162B1 (de) | 2008-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20190025047A (ko) | 뼈 장애, 연골 장애, 또는 이 둘 다의 관리 또는 개선을 위한 조성물 및 방법 | |
| JP5266254B2 (ja) | 選択的セロトニン再取り込み阻害組成物およびその方法 | |
| KR101202913B1 (ko) | 식물 추출물 및 그의 치료 용도 | |
| UA82895C2 (uk) | Застосування частин та/або екстрактів опунції для лікування депресій | |
| US20040126441A1 (en) | Development of an anti-cough, anti-tussive and throat soothing herbal formulation | |
| BR112021010952A2 (pt) | Uso de extrato de cóculo-hirsuto para tratamento de dengue | |
| US7338674B2 (en) | Anti-arthritic herbal composition and method thereof | |
| KR101083873B1 (ko) | 애엽에 함유되어 있는 혈액응고 억제작용을 갖는 성분의 제거방법 | |
| JP2002510640A (ja) | エイズの予防及び治療用薬草組成物 | |
| JP2729340B2 (ja) | 痴呆症治療剤 | |
| KR102428859B1 (ko) | 안전성이 확보된 소화기계 질환 예방 또는 치료를 위한 경구투여용 약학 조성물 | |
| Sekar | EVALUATION OF ANTIOXIDANT POTENTIALS OF HEDYOTIS DIFFUSA AND LOBELIA CHINENSIS BY AN INVITRO STUDY | |
| MXPA06004673A (en) | Use of prickly pear (opuntia) plant parts and/or extracts for the treatment of depressions | |
| KR20230062094A (ko) | 육계 추출물 및 무기화합물을 포함하는 약학적 조성물 | |
| KR20190067654A (ko) | 지칭개 추출물을 유효성분으로 함유하는 항염증 조성물 | |
| CN111728985A (zh) | 一种以蛤蟆油为主要成分的组合物及其用途 | |
| KR20090069418A (ko) | 꽃향유 추출물 및 그 용도 | |
| JPH01172336A (ja) | 豚のヘモフィルス感染症の予防及び治療剤 | |
| JPS6127919A (ja) | 利胆剤 | |
| KR20040058736A (ko) | 항보체 활성작용을 갖는 가래나무 추출물 | |
| JP2013079290A (ja) | 安中散末および四逆散エキス含有経口組成物 | |
| JP2008019250A (ja) | 安中散末および四逆散エキス含有経口組成物 |